Scholarlink

<p>The standard therapy for obstructive sleep apnea (OSA) is continuous positive airway pressure therapy (CPAP). CPAP and other therapies such as mandibular advancement splints or hypoglossal nerve stimulation lead to positive effects in terms of sleep quality, disease-specific quality of life, and neurocognitive function. The treatment of symptomatic OSA therefore requires effective therapy over the entire duration of the disease/lifespan. However, 30–50% of patients discontinue CPAP therapy within the first 5&#xa0;years after initiation. Despite this, only about 1–2% of affected patients currently receive second-line therapy. Effective therapy management of patients with OSA aims for the shortest possible “time to effective therapy” and the longest possible “time on effective therapy” over the entire duration of the disease/lifespan. The S-O-S questionnaire, which measures patient satisfaction (= S), reduction in apnea burden (Outcome = O), and symptoms (= S; S‑O‑S criteria), is presented as a&#xa0;contribution to a&#xa0;strategy for the structured long-term care of patients with OSA therapy. In long-term care, patients with OSA whose therapy needs to be optimized or is unsuitable should be identified at an early stage and thus treated promptly. New strategies for the long-term care of OSA patients with the aim of extending the time on effective therapy of OSA over the entire duration of the lifespan should be evaluated in the context of care studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapy management of patients with obstructive sleep apnea

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月16日

查看全文
  • Michael Arzt,
  • Christoph Schoebel,
  • Wolfgang Galetke,
  • Holger Woehrle

摘要

The standard therapy for obstructive sleep apnea (OSA) is continuous positive airway pressure therapy (CPAP). CPAP and other therapies such as mandibular advancement splints or hypoglossal nerve stimulation lead to positive effects in terms of sleep quality, disease-specific quality of life, and neurocognitive function. The treatment of symptomatic OSA therefore requires effective therapy over the entire duration of the disease/lifespan. However, 30–50% of patients discontinue CPAP therapy within the first 5 years after initiation. Despite this, only about 1–2% of affected patients currently receive second-line therapy. Effective therapy management of patients with OSA aims for the shortest possible “time to effective therapy” and the longest possible “time on effective therapy” over the entire duration of the disease/lifespan. The S-O-S questionnaire, which measures patient satisfaction (= S), reduction in apnea burden (Outcome = O), and symptoms (= S; S‑O‑S criteria), is presented as a contribution to a strategy for the structured long-term care of patients with OSA therapy. In long-term care, patients with OSA whose therapy needs to be optimized or is unsuitable should be identified at an early stage and thus treated promptly. New strategies for the long-term care of OSA patients with the aim of extending the time on effective therapy of OSA over the entire duration of the lifespan should be evaluated in the context of care studies.